MA35271B1 - Antagonistes de trpm8 et leur utilisation dans des traitements - Google Patents

Antagonistes de trpm8 et leur utilisation dans des traitements

Info

Publication number
MA35271B1
MA35271B1 MA36692A MA36692A MA35271B1 MA 35271 B1 MA35271 B1 MA 35271B1 MA 36692 A MA36692 A MA 36692A MA 36692 A MA36692 A MA 36692A MA 35271 B1 MA35271 B1 MA 35271B1
Authority
MA
Morocco
Prior art keywords
disorders
trpm8
compounds
antagonists
treatments
Prior art date
Application number
MA36692A
Other languages
English (en)
Inventor
Kaustav Biswas
James Brown
Jian J Chen
Vijay Keshav Gore
Scott Harried
Daniel B Horne
Matthew R Kaller
Qingyian Liu
Vu Van Ma
Holger Monenschein
Thomas T Nguyen
Chester Chenguang Yuan
Wenge Zhong
Jean David J St Jr
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA35271B1 publication Critical patent/MA35271B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'invention concerne des composés de formule (i) servant comme antagonistes de trpm8. De tels composés servent à traiter une pluralité de troubles et maladies à médiation par trpm8 et peuvent être utilisés pour préparer des médicaments et des compositions pharmaceutiques servant à traiter de tels troubles et maladies. De tels troubles peuvent être, de façon non exhaustive, les migraines et les douleurs neuropathiques. Les composés de formule (i) ont une structure dont les définitions des variables sont fournies ici.
MA36692A 2011-06-24 2014-01-20 Antagonistes de trpm8 et leur utilisation dans des traitements MA35271B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500843P 2011-06-24 2011-06-24
PCT/US2012/043566 WO2012177893A2 (fr) 2011-06-24 2012-06-21 Antagonistes de trpm8 et leur utilisation dans des traitements

Publications (1)

Publication Number Publication Date
MA35271B1 true MA35271B1 (fr) 2014-07-03

Family

ID=46384521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36692A MA35271B1 (fr) 2011-06-24 2014-01-20 Antagonistes de trpm8 et leur utilisation dans des traitements

Country Status (23)

Country Link
US (3) US8710043B2 (fr)
EP (1) EP2723717A2 (fr)
JP (1) JP2014527511A (fr)
KR (1) KR20140045507A (fr)
CN (1) CN103906733A (fr)
AP (1) AP2013007331A0 (fr)
AR (1) AR086750A1 (fr)
AU (1) AU2012272895B2 (fr)
BR (1) BR112013033316A2 (fr)
CA (1) CA2839699A1 (fr)
CL (1) CL2013003715A1 (fr)
CO (1) CO6852073A2 (fr)
CR (1) CR20140037A (fr)
EA (1) EA201490152A1 (fr)
MA (1) MA35271B1 (fr)
MX (1) MX2013015274A (fr)
MY (1) MY157429A (fr)
PE (1) PE20140868A1 (fr)
PH (1) PH12013502611A1 (fr)
TN (1) TN2013000529A1 (fr)
TW (2) TW201429948A (fr)
UY (1) UY34160A (fr)
WO (1) WO2012177893A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2016053855A1 (fr) 2014-09-29 2016-04-07 The Scripps Research Institute Modulateurs du récepteur de la sphingosine -1-phosphate pour le traitement de troubles cardio-pulmonaires
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
AU2017285609B2 (en) * 2016-06-13 2022-08-18 Mitsubishi Tanabe Pharma Corporation Compositions for treating or preventing vasomotor symptoms
JP2020524717A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
CA3067257A1 (fr) 2017-06-22 2018-12-27 Curadev Pharma Limited Modulateurs a petites molecules de sting humain
JP7265551B2 (ja) * 2017-12-19 2023-04-26 田辺三菱製薬株式会社 血管運動症状を治療または予防するための組成物および方法
JP2021523092A (ja) * 2018-03-21 2021-09-02 ピラマル・ファーマ・リミテッドＰｉｒａｍａｌ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ アルファ−（ジアリールメチル）アルキルアミンの改良された不斉合成
EP3781547A4 (fr) * 2018-04-18 2022-04-13 Piramal Pharma Limited Synthèse asymétrique améliorée d'amines chirales alpha-ramifiées
MX2021012310A (es) 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
BR112022024476A2 (pt) * 2020-06-17 2022-12-27 Merck Sharp & Dohme Llc 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
EP4167994A4 (fr) * 2020-06-17 2024-07-24 Merck Sharp & Dohme LLC 2-oxoimidazolidine-5-carboxamides utiles en tant qu'inhibiteurs de nav1.8
JP7323723B2 (ja) 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115108980B (zh) * 2022-06-22 2023-06-16 济南大学 一种2-甲基喹啉类化合物的4号位酰基化衍生物的制备方法
CN120025283B (zh) * 2023-11-28 2026-01-09 成都地奥制药集团有限公司 酰胺类化合物及其用途
CN119118901B (zh) * 2024-09-09 2025-09-30 中国人民解放军北部战区总医院 一种氧吲哚类衍生物及其制备方法与在trpa1抑制剂方向的应用

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483250A (en) * 1949-09-27 Tt a it tt
DE2417763A1 (de) 1974-04-11 1975-10-30 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2428673A1 (de) 1974-06-14 1976-01-02 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5081131A (en) 1986-01-13 1992-01-14 American Cyanamid Company Omega-((hetero)alkyl)benz(cd)-indol-2-amines
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5380721A (en) 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
WO1992012973A1 (fr) 1991-01-23 1992-08-06 Nippon Kayaku Kabushiki Kaisha Derive de chromane
ES2036926B1 (es) 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE4138819A1 (de) 1991-11-26 1993-05-27 Basf Ag Hydroxypyridoncarbonsaeureamide, deren herstellung und verwendung
GB9127041D0 (en) 1991-12-20 1992-02-19 Fujisawa Pharmaceutical Co New use
FR2692895A1 (fr) 1992-06-26 1993-12-31 Adir Nouveaux 1-oxo 2,4,5,6-tétrahydro 2,3,7-triazaphénalènes leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
EP0653434A1 (fr) 1993-11-12 1995-05-17 Tanabe Seiyaku Co., Ltd. Dérivés de glucosamine, leur procédé de préparation et leur intermédiaires
BR9510360A (pt) 1994-12-23 1997-12-23 Thomae Gmbh Dr K Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação
JPH11501934A (ja) 1995-03-14 1999-02-16 シャスカン，エドワード・ジー ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IN186549B (fr) 1995-04-19 2001-09-29 Kumiai Chemical Co Ltd
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
DE19523087A1 (de) 1995-06-26 1997-01-02 Bayer Ag 1,3-Oxa(thia)zin-Derivate
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
GB9525828D0 (en) 1995-12-18 1996-02-21 Bayer Ag Use of hetarylacetic acid derivatives
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
ATE259800T1 (de) 1998-01-21 2004-03-15 Banyu Pharma Co Ltd Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
AU761737B2 (en) 1998-06-03 2003-06-12 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US5910595A (en) 1998-06-26 1999-06-08 Salsbury Chemicals, Inc. Process for preparing oximidazoles
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
AU1684400A (en) 1998-12-11 2000-07-03 Sankyo Company Limited Substituted benzylamines
CA2348740A1 (fr) 1998-12-23 2000-07-06 Ruth R. Wexler Inhibiteurs de la thrombine ou du facteur xa
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
CZ290178B6 (cs) 1999-07-22 2002-06-12 Sankyo Company Limited Deriváty cyklobutenu
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
BR0013592A (pt) 1999-09-01 2002-05-07 Unilever Nv Embalagem comercial para alvejar manchas de tecido em um licor de lavagem aquoso, e, uso da mesma
BR0013593A (pt) 1999-09-01 2002-05-07 Unilever Nv Método para alvejar manchas de tecido
CA2383596A1 (fr) 1999-09-01 2001-03-08 Unilever Plc Composition et procede de blanchiment d'un substrat
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
CA2325358C (fr) 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
ES2225252T3 (es) 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
JP2003520850A (ja) 2000-01-28 2003-07-08 メラキュア セラピューティクス エービー 新規なメラノコルチン受容体作動薬および拮抗薬
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
AU2001259218A1 (en) 2000-04-27 2001-11-07 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
US20030050211A1 (en) 2000-12-14 2003-03-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Enzymatic detergent compositions
WO2002051396A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
AU2002242996A1 (en) 2001-03-29 2002-10-15 Tanabe Seiyaku Co., Ltd. Spiroisoquinoline compounds, methods for their preparation and intermediates
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
US6596718B1 (en) 2001-11-27 2003-07-22 Hoffmann-La Roche Inc. 7-Morpholin-4yl-benzothiazole amide derivatives
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
AR037746A1 (es) 2001-12-06 2004-12-01 Novartis Ag Compuestos derivados de amidoacetonitrilo, un procedimiento para su preparacion, un procedimiento para la preparacion de compuestos intermediarios, una composicion para combatir parasitos, un procedimiento para combatir dichos parasitos, y el empleo de dichos derivados para la preparacion de una com
SE0104248D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
JP4216196B2 (ja) 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
ES2360882T3 (es) 2002-03-28 2011-06-10 Merck Serono Sa Derivados de tiazolidina carboxamida como moduladores del receptor de prostaglandina f.
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
KR20040104643A (ko) 2002-04-26 2004-12-10 이시하라 산교 가부시끼가이샤 피리딘계 화합물 또는 이의 염 및 이들을 함유하는 제초제
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
FR2842805A1 (fr) 2002-07-29 2004-01-30 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
EP1546115A4 (fr) 2002-09-27 2010-08-04 Merck Sharp & Dohme Pyrimidines substituees
WO2004039795A2 (fr) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
WO2004058755A2 (fr) 2002-12-24 2004-07-15 Biofocus Plc Bibliotheques de composes
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
MXPA05012081A (es) 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Derivados de pirimidina sustituidos.
WO2005005392A1 (fr) * 2003-07-07 2005-01-20 Ionix Pharmaceuticals Limited Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels
CA2573951A1 (fr) 2003-07-18 2005-01-27 Virochem Pharma Inc. Composes spiro et procedes pour moduler une activite de recepteur de chimiokime
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
CA2537364A1 (fr) 2003-09-03 2005-03-10 Galapagos Nv Derives d'imidazo[1,5-a]pyridine ou d'imidazo[1,5-a]piperidine et leur utilisation dans la preparation d'un medicament dirige contre les troubles lies au recepteur 5-ht2a
GB0320983D0 (en) 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
EP1786816A4 (fr) 2003-09-10 2009-11-04 Virochem Pharma Inc Composes de spirohydantoine et procedes de modulation de l'activite des recepteurs de chimiokine
US7432281B2 (en) * 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US20050176767A1 (en) 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
CN1972914A (zh) 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
DE102004022897A1 (de) 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005115374A1 (fr) 2004-05-29 2005-12-08 7Tm Pharma A/S Ligands du recepteur crth2 utilises a des fins therapeutiques
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
DE102004031323A1 (de) 2004-06-29 2006-01-19 Bayer Cropscience Ag Substituierte Pyridazincarboxamide und Derivate hiervon
KR20070063526A (ko) * 2004-08-30 2007-06-19 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제인 우레아 유도체
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
US20080051418A1 (en) 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative
EP1831194A4 (fr) * 2004-12-21 2009-12-02 Astrazeneca Ab ANTAGONISTES HETEROCYCLIQUES DE MCHr1 ET LEURS APPLICATIONS THERAPEUTIQUES
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20080207677A1 (en) 2004-12-31 2008-08-28 Gpc Biotech Ag Napthyridine Compounds As Rock Inhibitors
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
WO2006094246A2 (fr) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Modulateurs de sirtuine a base de n-arylmethyl benzamide
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
CA2611376C (fr) 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Agents therapeutiques
WO2007002563A1 (fr) 2005-06-27 2007-01-04 Exelixis, Inc. Régulateurs de lxr de type imidazole
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007017093A1 (fr) 2005-08-04 2007-02-15 Bayer Healthcare Ag Derives amides d'acide 2-benzyloxy-benzoique substitue
EP1764098A1 (fr) 2005-09-17 2007-03-21 Speedel Experimenta AG Dérivés de diaminoalcols et leur utilization pour le traitement de la malaria, de la maladie d'Alzheimer et du SIDA
PL1948176T3 (pl) 2005-11-10 2011-05-31 Bayer Schering Pharma Ag Diarylomoczniki do leczenia nadciśnienia płucnego
EP1948172A1 (fr) 2005-11-10 2008-07-30 Bayer HealthCare AG Diaryle-urees servant a traiter une neuropathie diabetique
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
WO2007068381A1 (fr) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryle-urees pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
WO2007068383A1 (fr) 2005-12-15 2007-06-21 Bayer Healthcare Ag Urees de diaryle pour le traitement d'infections virales
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
WO2007086799A1 (fr) 2006-01-27 2007-08-02 Astrazeneca Ab Quinoléines substituées par un amide
EP1987037A2 (fr) 2006-02-23 2008-11-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
ES2566481T3 (es) * 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
EP2338488A1 (fr) 2006-05-26 2011-06-29 Bayer HealthCare, LLC Associations de médicaments comportant des urées de diaryle
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
WO2008003746A1 (fr) 2006-07-06 2008-01-10 Bayer Cropscience Sa Nouveaux dérivés de n-(4-pyridin-2-ylbutyle) carboxamide, procédé de préparation et utilisation comme fongicides
CA2658793A1 (fr) 2006-07-25 2008-02-07 Daniel Dumas Derives de quinoline
CA2661459A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Amides di-aromatiques substitues en tant qu'inhibiteurs de la glyt1
US7834023B2 (en) 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008056687A1 (fr) 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors
AU2007321922A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
WO2008073825A1 (fr) 2006-12-08 2008-06-19 Exelixis, Inc. Modulateurs lxr et fxr
WO2008080015A2 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et procédés pour la modulation des kinases, et indications correspondantes
US20080293711A1 (en) 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
AU2008239754A1 (en) 2007-04-11 2008-10-23 Merck Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
EP2161996B1 (fr) 2007-06-05 2014-07-16 Merck Sharp & Dohme Corp. Antagonistes des récepteurs cgrp à base de carboxamide hétérocyclique
EP2178866A2 (fr) 2007-07-09 2010-04-28 AstraZeneca AB Derives de pyrimidine trisubstitues pour le traitement de maladies proliferatives
US20120121540A1 (en) 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
CA2696725A1 (fr) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Derives de pyridine et leurs procedes d'utilisation
WO2009038812A1 (fr) 2007-09-20 2009-03-26 Amgen Inc. Dérivés de pipéridine condensée, utiles en tant que ligands des récepteurs vanilloïdes
WO2009073203A1 (fr) 2007-12-04 2009-06-11 Amgen Inc. Ligands du récepteur trp-m8 et leur utilisation dans des traitements
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
JP5557832B2 (ja) 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
AR071310A1 (es) 2008-04-11 2010-06-09 Merck Serono Sa Sulfonamidas
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2299813B1 (fr) 2008-06-12 2015-12-16 Merck Sharp & Dohme Corp. Quinoléines 3- et 6-substituées ramifiées en tant qu antagonistes de récepteur cgrp
CA2729050A1 (fr) 2008-06-25 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Dyaryle-urees pour le traitement de l'insuffisance cardiaque
ES2610882T3 (es) * 2008-08-19 2017-05-03 Janssen Pharmaceutica, N.V. Antagonistas del receptor al mentol frío
CN101343313B (zh) 2008-09-03 2011-11-16 南京农业大学 一种葡萄糖二肽类化合物及其制备方法和用途
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
EP2337563B1 (fr) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulateurs de l'activité de l'aldéhyde déshydrogénase et leurs procédés d'utilisation
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
UY32525A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
MX2011011428A (es) * 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
EP2445914B1 (fr) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DÉRIVÉS DE 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-ACID CARBOXYLIQUE AMIDES
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
WO2011014649A1 (fr) 2009-07-29 2011-02-03 Duke University Compositions et procédés destinés à inhiber la croissance des poils
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
EP2521553A4 (fr) 2010-01-06 2013-08-28 Errico Joseph P Méthodes et compositions pour le développement de médicaments ciblés
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
WO2011106632A1 (fr) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Acides hydroxamiques substitués et leurs utilisations
JPWO2011142359A1 (ja) 2010-05-10 2013-07-22 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
US8669252B2 (en) 2010-05-17 2014-03-11 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
BR112012030184A2 (pt) 2010-05-27 2015-12-29 Bayer Cropscience Ag derivados de ácido piridinilcarboxílico como fungicidas
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
PH12013500907A1 (en) 2010-11-05 2013-07-08 Firmenich Incorporated Compounds useful as modulators of trpm8
CA2820362C (fr) 2010-12-08 2020-03-24 The United States Of America, As Represented By The Secretary, Departmt Of Health And Human Services Utilisation des pyrazolopyrimidines substituees comme activateurs de glucocerebrosidase
WO2012082862A2 (fr) 2010-12-14 2012-06-21 Beth Israel Deaconess Medical Center Inhibiteurs du récepteur des androgènes et leurs procédés d'utilisation
AU2010365740B2 (en) 2010-12-15 2015-12-24 Ppg Europe Bv Drier composition and use thereof
WO2012083190A1 (fr) 2010-12-17 2012-06-21 The Rockefeller University Antagonistes de récepteurs olfactifs d'insecte
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
WO2012120398A1 (fr) 2011-03-04 2012-09-13 Pfizer Limited Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用

Also Published As

Publication number Publication date
TN2013000529A1 (en) 2015-03-30
JP2014527511A (ja) 2014-10-16
AR086750A1 (es) 2014-01-22
AP2013007331A0 (en) 2013-12-31
US20140171639A1 (en) 2014-06-19
MY157429A (en) 2016-06-15
TW201311643A (zh) 2013-03-16
CN103906733A (zh) 2014-07-02
UY34160A (es) 2012-08-31
CO6852073A2 (es) 2014-01-30
WO2012177893A2 (fr) 2012-12-27
TW201429948A (zh) 2014-08-01
EP2723717A2 (fr) 2014-04-30
CA2839699A1 (fr) 2012-12-27
AU2012272895A1 (en) 2013-04-11
TWI448454B (zh) 2014-08-11
US8710043B2 (en) 2014-04-29
WO2012177893A3 (fr) 2013-06-13
US20130157996A1 (en) 2013-06-20
US9096527B2 (en) 2015-08-04
CR20140037A (es) 2014-03-13
KR20140045507A (ko) 2014-04-16
MX2013015274A (es) 2014-03-31
PH12013502611A1 (en) 2014-04-28
PE20140868A1 (es) 2014-07-18
BR112013033316A2 (pt) 2017-01-31
CL2013003715A1 (es) 2014-06-27
US20140171406A1 (en) 2014-06-19
EA201490152A1 (ru) 2014-05-30
AU2012272895B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
EA200901373A1 (ru) Аминогетероциклические соединения
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MA35444B1 (fr) Ligands du récepteur ep1
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines